PolymarketVérifier la disponibilitéSans KYCDonnées de résolution vérifiéesBien calibréAlerte qualité des donnéesAucune cotation en direct
Données au 5 oct. 2026, 22:11 UTC · politique pm-quality-4
Probabilité implicite actuelle
June 30, 83%
June 30, 83%Qualité du marché
≤49 / 100
Faible qualitéVolume 24h
—
Liquidité
7 k €
Liquidité moyenneAchat / Vente
82.0% / 83.0%
Écart
1.0 pt
Spread serréCommentaires
0
Données du marché
Mis à jour il y a 5 minutes
19 août 26, 18:47 UTC1 juil. 27, 03:59 UTC
Tendances
Conditions de la plateforme
Source : Polymarket
Ces conditions sont indicatives ; les opérations simulées de CoinRithm suivent leurs propres règles.
- Ordre minimum (parts):
- 5
- Pas de cotation:
- 1 points de pourcentage
- Frais:
- Oui
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
FDA approves skin cancer vaccine by which date?
PolymarketIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsWill the Russian cancer vaccine work?
Manifold MarketsIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsWhat will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWill CDC cut the childhood vaccine schedule below 11 diseases in 2026?
KalshiRègles
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA).
- An original BLA or a resubmission of such a BLA following FDA action will qualify.
- The application may cover any indication.